Health Canada — Medical Devices · Canada · 2021-10-08 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Reported risk: Based on an unusual rate of complaints from the field for "substrate error" leading to a potential delayed results on different Vidas References tested on all Vidas? Systems, Biomerieux initiated an investigation. The substrate error issue was confirmed on all lots of Vidas? Immuno-Assays manufactured with substrate batches using the common lot of raw material (4-MUP). The only potential risk associated with the substrate error is a delayed result as you need to run another test. There is no risk of false results. The investigation demonstrates that the issue occurs over the product shelf-life. The analyzes of the kinetic model allowed to define a revised expiry date for each impacted lot of Vidas? Immuno-Assays finished products. When used until the revised expiry date, the product continues to perform per its registered performance specifications
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.